At DDW Medical Conference, Dynavax (DVAX) Presents Additional Phase 3 Data for HEPLISAVTM Hepatitis B Vaccine
More News related to DVAX
- Dynavax Completes Enrollment of First Cohort of Patients in Phase 1b Clinical Trial for Hepatitis B Therapy
- Dynavax Technologies (DVAX) To Purchase Symphony Dynamo; Will Acquire $20M in Cash and Hep C and Cancer Rights
- Dynavax to Acquire Symphony Dynamo, Inc., Including $20 Million in Unrestricted Cash
- Dynavax Appoints Francis R. Cano, Ph.D. to Board of Directors
- Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients
Dynavax Technologies Corporation (Nasdaq: DVAX) presented additional Phase 3 clinical data for HEPLISAVTM hepatitis B vaccine in a poster session at the Digestive Disease Week (DDW) medical conference in Chicago. In addition to meeting its primary endpoint in this Phase 3 trial as previously reported, HEPLISAV provided more rapid and increased seroprotection against hepatitis B viral infection and with fewer doses than the licensed vaccine. The data show the differences to be particularly significant in the subset of subjects over 40 years of age who are usually less likely to respond to immunization.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.03Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
